Merck & Co., Inc.
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Lenvima (lenvatinib by Year
Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. reported growth YoY (%) (%)
Merck Lenvima (lenvatinib: 4.0% in FY2025, down 3.0 pts from a year earlier.
Latest, FY2025
4.0%
Period ended Dec 31, 2025
Change on a year earlier
-3.0 pts
7.0% in FY2024
History
5 years
Since FY2019
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Alliance Revenue – Lenvima (2) | 1,053 | 1,010 | 4 | 737 | 705 | 4 | 316 | 305 | 4”
Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Lenvima (lenvatinib — Eisai oncology alliance revenue) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.0% | -3.0 pts | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 7.0% | -6.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 13.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 16.0% | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | 152.0% | – | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
Cite this data
StockData. (2026). Merck Lenvima (lenvatinib (%), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-lenvima-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.